New hope for kids with sickle cell: stem cell transplant from mismatched blood type donors
NCT ID NCT03214354
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a stem cell transplant for children with sickle cell disease who have a matched family donor whose blood type is incompatible. The goal is to see if a gentle conditioning regimen using alemtuzumab, low-dose radiation, and sirolimus can safely allow the transplant to work. Up to 12 children aged 1 to 18 will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cell transplant with alemtuzumab, total body irradiation, and sirolimus
- What this could lead to
- If successful, this could offer a new transplant option for children with sickle cell disease who have a matched family donor with a different blood type.
- What could go wrong
- This is a small early-phase trial with only 12 participants, so results may not apply broadly. Risks include graft failure, pure red cell aplasia, and side effects from immune suppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PURE RED CELL APLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alberta Children's Hospital
RECRUITINGCalgary, Alberta, T3B 6A8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease